Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.

Journal of neuroimmunology - 15 Oct 2020

Ibrahim Samar H, El-Mehdawy Karim M, Seleem Mae, El-Sawalhi Maha M, Shaheen Amira A

Abstract excerpt

Relapsing remitting multiple sclerosis (RRMS) is the most prevalent MS subtype. Years after disease onset, most of RRMS patients show transition into secondary progressive form (SPMS). Currently, no biomarkers are available for tracking disease progression. Here, we observed marked elevation of Rho-associated protein kinase 2 (ROCK2) along with significant downregulation of miRNAs 300 and 450b-5p expressions in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MicroRNAs

Share to Multiple Sclerosis, Chronic Progressive

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Persons with Disabilities

Share to rho-Associated Kinases

Source

Identifiers

PMID: 32781341
DOI: 10.1016/j.jneuroim.2020.577356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.PMID 32781341Read ↗

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patientsSemantic proximity Read ↗

Association between circulating MicroRNAs (hsa-miR-92a-1* and hsa-miR-454) and multiple sclerosis phenotypes and activity status.Semantic proximity Read ↗

Identification of MS-specific serum miRNAs in an international multicenter studySemantic proximity Read ↗

Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up studySemantic proximity Read ↗

Circulating microRNAs as biomarkers in progressive multiple sclerosisSemantic proximity Read ↗

Multiple Sclerosis Stages and their Differentially Expressed Genes: A Bioinformatics AnalysisSemantic proximity Read ↗

miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing–remitting multiple sclerosisSemantic proximity Read ↗

Altered Lnc-EGFR, SNHG1, and LincRNA-Cox2 Profiles in Patients with Relapsing-Remitting Multiple Sclerosis: Impact on Disease Activity and ProgressionSemantic proximity Read ↗

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort studySemantic proximity Read ↗

MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.Semantic proximity Read ↗

MAGI2-AS3 and miR-374b-5p as Putative Regulators of Multiple Sclerosis via Modulating the PTEN/AKT/IRF-3/IFN-β Axis: New Clinical InsightsSemantic proximity Read ↗

Identification of the miRNA-mRNA regulatory network in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.